Bridge to Life Ltd recalls Bridge to Life EasiSlush, (Sodium Chloride Solution for Sterile Slush…
The stated reason: The firm issued a field safety notice after becoming aware of three lots of products not having quarterly dose audits being completed on time in the first quarter of 2024.
Bridge to Life Ltd began a medical device recall on June 12, 2025 whose reported distribution included Ohio. FDA
What the record shows
Routine lot by lot testing was completed properly however the quarterly dose audit (sampling/testing to monitor the gamma steri… FDA graded it Class II — use may cause temporary or medically reversible health consequences. Quantity affected: 4528 units. The recall is listed as ongoing. FDA
Context
By the numbers
- Date of record: June 12, 2025 FDA
- Recall number: Z-2157-2025 FDA
- Recalls in this action: 1 FDA
- Recalling firm: Bridge to Life Ltd FDA
- Product: Bridge to Life EasiSlush, (Sodium Chloride Solution for Sterile Slush Preparation) (0.9% Sodium Chloride Irrigation… FDA
- Reason for recall: The firm issued a field safety notice after becoming aware of three lots of products not having quarterly dose audits… FDA
Assembled mechanically from the source filing and The Lantern's own record database — no AI-written prose. Every figure above appears verbatim in the cited record, which is linked on this page. FDA
Sources
The source filing
| Recall number | Z-2157-2025 |
|---|---|
| Recalls in this action | 1 |
| Recalling firm | Bridge to Life Ltd |
| Product | Bridge to Life EasiSlush, (Sodium Chloride Solution for Sterile Slush Preparation) (0.9% Sodium Chloride Irrigation, USP), Part Number REF BTLE-1250 |
| Reason for recall | The firm issued a field safety notice after becoming aware of three lots of products not having quarterly dose audits being completed on time in the first quarter of 2024. Routine lot by lot testing was completed properly however the quarterly dose audit (sampling/testing to monitor the gamma sterilization process and confirm the validated parameters remain effective to assure sterility and bioburden reduction per requirements) was not completed on time. |
| Classification | Class II — use may cause temporary or medically reversible health consequences |
| Recall type | medical device |
| Quantity | 4528 units |
| Status | Ongoing |
| Voluntary or mandated | Voluntary: Firm initiated |
| Initiated | 20250612 |
| Reported | 20250730 |
| Distribution | United States - New York, Maryland, Alabama, North Carolina, South Carolina, Ohio, Florida, Wisconsin, Utah, Tennessee, New Jersey, Georgia, Nebraska, Arizona, Minnesota, California, and Canada |
| Firm location | Northbrook, IL, United States |
Published by U.S. Food and Drug Administration (openFDA). This is the agency's public filing as The Lantern received it, shown with its fields named in plain English.